Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Search results

Found 17418 matches for

Do you want to know more about Open Access? Find out about Act on Acceptance & ORCID from an expert? Book a place for our session on Tuesday 23rd August, 2-3pm in Room B at the WTCHG. Juliet Ralph, the Open Access Subject librarian, will be available for your toughest questions.

CTMGH logo for News

OCGHR files

News files

How to create podcasts

Symplectic guide

SOPs

GRAM project

GRAM (Global Research on Antimicrobial resistance), brings together researchers from around the world to develop the evidence base for understanding one of our most pressing global health challenges, the threat of antimicrobial resistance.

Postgraduate Diploma in Global Health Research

Summary

Files Library

Events files

Tropical Immunology

Antimicrobial resistance, antimicrobial consumption and burden estimation

Drug-Resistant Infections and Disease Dynamics group

The social science, ethics and community engagement network

Study with us files

MSc Modelling for Global Health

Haiku guide

MSc Modelling for Global Health Team

MSc Modelling in Global Health

The MSc in Modelling for Global Health is a full-time one-year taught programme that provides interdisciplinary content on modelling, health evidence to inform the modelling, and policy processes to inform decisions. Week-long modules are delivered through a mix of interactive practical sessions and lectures in person at Oxford. Demand for a skilled workforce in this field is on the rise and there is great potential for mathematical and economic modelling to help guide policy for national health systems and international policymaking.

Forms library

TropMed webinars files

Load More

Similar stories

RECOVERY trial team members appointed MBEs

Two RECOVERY Trial team members have been recognised in the New Year Honours list 2022. RECOVERY Trial coordinator, Professor Richard Haynes, has been appointed Member of the Order of the British Empire (MBE) for services to Global Health, and Senior Clinical Trial Manager, Lucy Fletcher, has been appointed MBE for services to Clinical Trials. The New Year Honours list recognises outstanding achievements by a wide range of extraordinary people from across the United Kingdom. People are awarded honours for achievements in their field of work (including health, education, science and technology), as well as for making a difference to their community.

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include OUCRU in Vietnam and institutions in Canada, Chile, Australia and the UK. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Oxford retains top spot in world rankings for sixth consecutive year

The University of Oxford remains top of the table in latest Times Higher Education World University Rankings. In a year dominated by the ongoing Covid-19 pandemic, the rankings reflect the vital role of universities in understanding and managing the crisis as a number of institutions around the world saw significant boosts in their citation scores from Covid-19 focused research.

OUCRU scientists identify combination of biological markers associated with severe dengue

Nguyen Lam Vuong, Sophie Yacoub & colleagues have identified a combination of biological markers in patients with dengue that could predict whether they go on to develop moderate to severe disease. Biomarkers are used to identify the state or risk of a disease in patients; these findings could aid the development of biomarker panels for clinical use and help improve triage and risk prediction in patients with dengue.

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

RECOVERY trial finds aspirin does not improve survival for patients hospitalised with COVID-19

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for patients hospitalised with COVID-19. Patients with COVID-19 are at increased risk of blood clots forming in their blood vessels, particularly in the lungs. Between November 2020 and March 2021, the RECOVERY trial included nearly 15,000 patients hospitalised with COVID-19 in an assessment of the effects of aspirin, which is widely used to reduce blood clotting in other diseases. There was no significant difference in the primary endpoint of 28-day mortality